DarioHealth/DRIO

$1.23

-14.87%
-
1D1W1MYTD1YMAX

About DarioHealth

DarioHealth Corp. is a global digital therapeutics (DTx) company. The Company operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and highly engaging digital therapeutic interventions. Its platform and suite of solutions delivers personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Its products include Dario Blood Pressure Monitoring System and Dario Blood Glucose Monitoring Starter Kit. Dario Blood Glucose Monitoring Starter Kit is a pocket-sized smartphone glucometer that manages diabetes in one ultra-compact device. Dario Blood Pressure Monitoring System is a blood pressure monitoring system used to measure blood pressure, which allows to store all its user readings in the Dario App. Its Dario mobile app is a complete, cloud-based solution for personal chronic condition management.

Ticker

DRIO

Sector

Healthcare

Trading on

NASDAQ

Industry

Medical Equipment & Supplies

CEO

Erez Raphael

Employees

276

Headquarters

New york, United States

DarioHealth Metrics

BasicAdvanced
$36.21M
Market cap
-
P/E ratio
-$2.24
EPS
1.68
Beta
-
Dividend rate
$36.21M
1.68361
$4.58
$0.68
136.48K
3.789
3.383
42.293
49.094
-55.13%
-91.95%
-64.69%
1.779
0.575
3.263
-26.41%
21.69%
39.01%

What the Analysts think about DarioHealth

Analyst Ratings

Majority rating from 3 analysts.
Buy

Price Targets

Average projection from 3 analysts.
360.98% upside
High $8.00
Low $4.00
$1.23
Current price
$5.67
Average price target

DarioHealth Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-394.44% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$3.6M
2.86%
Net income
$-14.2M
-9.55%
Profit margin
-394.44%
-12.07%

DarioHealth Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 9.64%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.45
-$0.58
-$0.49
-$0.50
-
Expected
-$0.50
-$0.52
-$0.46
-$0.55
-$0.53
Surprise
-9.64%
11.11%
6.52%
-9.64%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for DarioHealth stock?

DarioHealth (DRIO) has a market cap of $36.21M as of April 15, 2024.

What is the P/E ratio for DarioHealth stock?

The price to earnings (P/E) ratio for DarioHealth (DRIO) stock is 0 as of April 15, 2024.

Does DarioHealth stock pay dividends?

No, DarioHealth (DRIO) stock does not pay dividends to its shareholders as of April 15, 2024.

When is the next DarioHealth dividend payment date?

DarioHealth (DRIO) stock does not pay dividends to its shareholders.

What is the beta indicator for DarioHealth?

DarioHealth (DRIO) has a beta rating of 1.68. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the DarioHealth stock price target?

The target price for DarioHealth (DRIO) stock is $5.67, which is 360.98% above the current price of $1.23. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell DarioHealth stock

Buy or sell DarioHealth stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing